NanoViricides

NanoViricides, Inc. is a development stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. The company was founded by Anil R. Diwan on April 1, 2005 and is headquartered in Shelton, CT.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NanoViricides, Inc. is a clinical stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. The company was founded by Anil R. Diwan on April 1, 2005 and is headquartered in Shelton, CT.

NanoViricides (NYSE-A:NNVC), a specialist in broad-spectrum antiviral medicines, believes its drug NV-387 could be crucial in fighting the bird flu virus H5N1. In recent studies, NV-387 outperformed three approved flu medications—Tamiflu (Oseltamivir), Rapivab (Peramivir), and Xofluza (Baloxavir)—in treating severe lung infections caused by the Influenza A/H3N2 virus in animals.

NanoViricides hails the potential of NV-387 in combatting bird flu virus H5N1

SHELTON, CT / ACCESSWIRE / June 24, 2024 / NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, comments that the ultra-broad-spectrum antiviral NV-387 could be an important weapon against bird flu H5N1 viruses.

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides

NanoViricides (NYSE-A:NNVC) announced that its ultra-broad-spectrum antiviral drug candidate NV-387 demonstrated effectiveness in protecting lungs from damage from Influenza A H3N2 in a lethally infection mouse model. Investors welcomed the news, sending shares of NanoViricides (NYSE-A:NNVC) up 11% to US$1.82 in early trade on Thursday.

NanoViricides says antiviral drug candidate shows promise in protecting lungs against Influenza A

SHELTON, CT / ACCESSWIRE / June 20, 2024 / NanoViricides, Inc. (NYSE AmerIcan.:NNVC) (the "Company"), a clinical stage company and global leader in broad-spectrum antiviral nanomedicines, reports that the ultra-broad-spectrum antiviral NV-387, a clinical Phase II stage drug candidate, was found to be effective in protecting lungs from damage in a lethally infected Influenza A H3N2 mouse model.

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model

NanoViricides (NYSE-A:NNVC) said its lead antiviral candidate, NV-387, was found to be highly active when taken orally, making potentially the first nanomedicine to be effective in this way.  NV-387 demonstrated an ideal flat blood concentration profile for extended periods upon oral administration in animal models, the company found, which it said allows for sustained antiviral effects with infrequent dosing.

NanoViricides antiviral candidate 'may be first effective oral nanomedicine'

A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More SHELTON, CT / ACCESSWIRE / June 11, 2024 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, reports that its clinical stage lead nanoviricide broad-spectrum antiviral drug candidate, NV-387, results in an ideal flat blood concentration profile for an extended time period upon oral administration in two different animal models.

Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect

NanoViricides (NYSE-A:NNVC) has unveiled additional positive data for its lead clinical-stage broad-spectrum antiviral agent NV-387, a desirable blood concentration profile that it believes could enable infrequent dosing. The company said when administered intravenously in a non-human primate animal model, NV-387 demonstrated a “highly desirable blood concentration profile.

NanoViricides says lead asset exhibits desirable blood concentration profile for infrequent dosing

A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More SHELTON, CT / ACCESSWIRE / June 4, 2024 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, reports on the highly desirable blood concentration profile of its lead clinical stage broad-spectrum antiviral agent NV-387 upon intravenous (I.V.

The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect

NanoViricides (NYSE-A:NNVC) is developing a first-in-class, broad-spectrum anti-viral agent NV-387 that it believes could revolutionize the treatment of viral infections including RSV, COVID, and influenzas. CEO Dr Anil Diwan told investors that, if approved, NV-387 could be “as revolutionary an antiviral agent as penicillin was as an anti-bacterial agent.

NanoViricides CEO says lead asset NV-387 could be ‘holy grail' of antiviral medicines

NanoViricides (NYSE-A:NNVC) announced that it has engaged Chicago-based life sciences consultancy firm Aagami for business development, specifically to seek out licensing and partnering opportunities for its assets and platform technology. The company said it is pursuing licensing and partnership opportunities for its lead asset NV-387 and its NanoViricides (NYSE-A:NNVC) platform technology.

NanoViricides taps Aagami to seek out licensing and partnership opportunities

NanoViricides (NYSE-A:NNVC) has been awarded a ‘Buy' rating and $6.50 price target by analysts at EF Hutton following the release of positive data on the anti-influenza A/H3N2 activity of its therapy NV-387. NanoViricides (NYSE-A:NNVC) shares traded hands at $2.17 on Tuesday afternoon.

NanoViricides could generate ‘antiviral superdrug' for multiple diseases, analysts believe

NanoViricides (NYSE-A:NNVC) has reported that its antiviral drug candidate NV-387 demonstrated significant efficacy against respiratory syncytial virus (RSV) in a lethal lung infection animal model. The study showed that animals treated with NV-387 orally had normal lung histology and survived the infection, suggesting NV-387 could potentially cure RSV.

NanoViricides reports strong antiviral activity of NV-387 against RSV

NV-387, A Broad-Spectrum Antiviral with Strong Activity Against RSV, Influenza A, Coronaviruses, Others SHELTON, CT / ACCESSWIRE / May 20, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says that the strong antiviral activity of NV-387 against RSV/A2 is clearly demonstrated by lungs remaining normal and showing no infection-related damage, when treated orally with NV-387, in a lethal lung RSV infection animal model. The animals in only the NV-387 treated group survived completely, as previously reported.

Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure

NV-387 Advancing to Phase II Clinical Trial for the Treatment of RSV Infection SHELTON, CT / ACCESSWIRE / May 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that it has filed its Quarterly Report on Form 10-Q for the fiscal second quarter ending March 31, 2024 with the Securities and Exchange Commission (SEC) on Tuesday, May 14, 2024. The report can be accessed at the SEC website by searching for the Company's filings.

NanoViricides Has Filed its Quarterly Report

NanoViricides (NYSE-A:NNVC) has released new data which shows the strength of the antiviral activity of its lead drug asset NV-387 in RSV/A2. The company said that animals lethally infected in their lungs with RSV achieved full survival upon NV-387 oral treatment.

NanoViricides unveils new data showing lead drug asset's strong activity against RSV

Complete Survival of Animals Lethally Infected into Lungs with RSV Achieved Upon NV-387 Oral Treatment SHELTON, CT / ACCESSWIRE / May 14, 2024 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says that antiviral activity of NV-387 against RSV/A2 is strong enough to have resulted in full survival of lethally infected animals was achieved.

A Novel Broad-Spectrum Antiviral with Activity Against RSV

NanoViricides (NYSE-A:NNVC) has released a slew of new data supporting the safety and ultra-broad antiviral activity of its investigational therapeutic NV-387. The company has recently released data from animal studies which shows that NV-387 shows strong antiviral activity against the “tripledemic” viruses - coronaviruses, RSV and influenza A viruses, including the Bird Flu H5N1 virus.

NanoViricides CEO discusses NV-387's broad-spectrum antiviral potential

NanoViricides (NYSE-A:NNVC) announced that members of its leadership team will be attending the EF Hutton Annual Global Conference being held in New York on May 15, 2024, which brings together institutional investors, high-net-worth individuals, corporate clients and the press with public and private company executives. At the conference, CEO Dr Anil Diwan will share with investors the company's progress over the last year.

NanoViricides to showcase lead drug asset's progress at EF Hutton Annual Global Conference

SHELTON, CT / ACCESSWIRE / May 10, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D.

NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City

NanoViricides (NYSE-A:NNVC) told investors that the ultra-broad antiviral activity spectrum of its lead drug asset NV-387 includes activity against the orthopoxvirus family of viruses, which includes Smallpox and Mpox, in both inhalation and sexual modes of transmission. In a lethal animal model of lung infection by the Ectromelia virus, a model for Smallpox and Mpox infection in humans, NV-387 led to an increase in the mice's lifespan comparable to oral treatment with approved Smallpox drug tecovirimat.

NanoViricides says lead asset shows antiviral activity against Smallpox and Mpox

NV-387 Possesses Strong Orthopoxvirus Activity Relevant to Both Sexual and Inhalation Modes of Transmission, Says NanoViricides SHELTON, CT / ACCESSWIRE / May 8, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says that the ultra-broad antiviral activity spectrum of NV-387 includes activity against orthopoxvirus family (Smallpox/Mpox), with both inhalation and skin abrasion (sexual) modes of infection acquisition. Ectromelia virus infection of mice is a model for Smallpox infection in humans, and also serves as a surrogate for MPox infection in humans.

A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox

NanoViricides (NYSE-A:NNVC) announced that its lead drug asset NV-387 has shown ultra-broad antiviral activity, including against Influenza A viruses.   The company said that in a lethal animal model of lung infection by Influenza A/H3N2 virus, NV-387 demonstrated “substantially superior antiviral effects” compared to three approved anti-influenza drugs, Oseltamivir, Peramivir, and Baloxivir.

NanoViricides drug asset shows ‘superior antiviral effects' against Influenza A

NV-387 Possesses Strong Anti-Influenza-A Virus Activity, and May Have Activity Against H5N1 Bird Flu Virus, Says NanoViricides SHELTON, CT / ACCESSWIRE / May 6, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says that the ultra-broad antiviral activity spectrum of NV-387 includes Influenza A viruses, possibly including Bird Flu H5N1 virus as well. NanoViricides reports that in a lethal animal model of lung infection by Influenza A /H3N2 virus, NV-387 was found to have substantially superior antiviral effects compared to three approved anti-influenza drugs.

A Novel Broad-Spectrum Antiviral with Activity Against Influenza A

Luna Innovations

Nano Dimension

Investors should keep their eyes on the global nanotechnology market, which was valued at USD 3.78 billion in 2022 and is expected to reach USD 74.1 billion by 2032, growing at a CAGR of 34.5% during the forecast period. The growth is attributed to the increasing adoption of nanotechnology in various industries such as electronics & semiconductor, automobiles, and more, leading to a boom for nanotech stocks.

3 Nanotech Stocks With the Potential to Make You an Overnight Millionaire

NanoViricides (NYSE-A:NNVC) announced that a Phase 1 trial of its investigational therapeutic NV-387 has been completed. The company, a leader in broad-spectrum antiviral nanomedicines, is developing NV-387 as a therapeutic for respiratory viral infections.

News for NanoViricides Stock (NNVC)